Business

Investing in Microcap Biotech Stocks

Investing in microcap biotech stocks can be lucrative. The market for microcap stocks has grown over the years, and many investors are taking advantage of the growth by investing in stocks that offer high returns. For example, some microcap biotech stocks have been in the news lately because of their potential to become blockbusters.

Actinium Pharmaceuticals

Founded in 2000, Actinium Pharmaceuticals is a clinical stage biotech company based in New York. The company develops innovative targeted immunotherapeutics and radiotherapies for cancer. Actinium’s technology platform delivers radioisotopes directly to cells of interest. These radioisotopes are designed to target various cancer targets, including immune cells.

The company’s two lead franchises are targeted payload immunotherapeutics and radiotherapies for targeted conditioning. These technologies combine the targeting abilities of antibodies with the cell killing abilities of radiation. Specifically, Actinium’s technology is designed to condition cells prior to bone marrow transplants. This enables engraftment of transplanted cells. It also reduces or eliminates the use of non-targeted chemotherapy.

One of Actinium’s lead products is Iomab-B, an Antibody Radiation Conjugate (ARC) used in hematopoietic stem cell transplantation. It is being studied in the SIERRA phase 3 clinical trial in patients with acute myeloid leukemia (AML).

Another product, Actimab-A, is an Actinium-225 based antibody radiation conjugate that has been studied in a variety of clinical trials. Actimab-A targets CD33, a validated target in AML. It is currently being studied in combination trials with venetoclax, a chemotherapy agent.

Actinium’s Antibody Radiation Conjugates are a highly potent form of targeted radiotherapy. Unlike conventional radiation therapies, they can target and destroy cancer cells with precision. These radioisotopes are delivered directly to cells of interest, which is intended to increase treatment success. They also have synergistic potential with other therapies.

Achillion Pharmaceuticals

Investing in microcap biotech stocks is risky. You can lose a lot of money. A microcap biotech stock is typically a company with a market capitalization of less than $300 million. These companies tend to be very speculative. Investing in microcap biotech stocks will not work unless you have a clear plan to protect your investment.

The first thing you should do when investing in biotech stocks is to look at the fundamentals of the company. The POWR Ratings System is one way to look at fundamentals. It uses 118 factors to determine a company’s rating.

One of the most important factors to look at is the company’s pipeline. Achillion’s pipeline is full of promising product candidates. Some of these candidates are in Phase 1 clinical trials, while others are in mid-stage development.

Achillion’s lead drug candidate is for the treatment of a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH). The company is expected to report interim data from the PNH study in the second quarter of 2017.

Achillion is also working with Janssen on an experimental drug called JNJ-4178. This drug is designed to treat treatment-naive chronic hepatitis C virus infection without cirrhosis. Janssen is currently conducting a Phase IIb clinical trial.

In addition to JNJ-4178, Achillion is working on drugs that target the alternate pathway of complement. This pathway is thought to play a critical role in several diseases.

Cassava Pharmaceuticals

Despite the fact that Cassava Pharmaceuticals (NASDAQ: SAVA) has been under scrutiny for a number of reasons, investors still think the company’s drug candidate has a lot of potential. Cassava Therapeutics is working to develop an oral drug called simufilam to combat Alzheimer’s disease. The drug is supposed to be able to improve cognition and reduce dementia. However, the company’s stock has been hit hard in recent years as the company has encountered several setbacks in its clinical trials.

A study done on Simufilam in Alzheimer’s patients showed that the drug improved patients’ reasoning and behavior. Researchers say the drug is supposed to repair an altered protein in the brain called FLNA. This protein interferes with normal functions of neurons.

The drug is also supposed to slow the decline of Alzheimer’s. Cassava Therapeutics’ study was open-label and the company tested the drug on only a few patients. The results showed that the drug improved patients’ cognition by about 10%. The study also showed that patients’ behavior improved by 29%.

Cassava Therapeutics is also working to develop a diagnostic test for Alzheimer’s disease. The test, called SavaDx, is based on a blood sample and detects the disease before the patient shows symptoms. If the diagnostic works, it could be a very lucrative asset for the company. However, the path to getting the diagnostic approved and commercialized is a bit longer than the path for the drug itself.

Moderna Covid-19 vaccine

Until COVID-19 hit the scene in the United States, Moderna, Inc. was a much smaller company. But now it is one of the leading biotechs seeking a vaccine for the disease. The company recently partnered with a major pharmaceutical company to develop a COVID-19 vaccine.

Today, Moderna’s stock price is only an inch higher than its closing price on Monday. However, the stock has fallen by nearly 50% since the company’s August 2021 highs. This might be a reflection of year-end profit-taking.

Moderna has filed for an updated COVID shot, a booster shot that will target two viral strains in one dose. The company also filed for a new vaccine candidate to treat cytomegalovirus. In addition, Moderna’s RSV vaccine is in phase 2/3 trials for older adults. But is a booster shot necessary?

The company has received financial support from the Coalition for Epidemic Preparedness Innovations, and it has been successful in getting a COVID-19 vaccine candidate to the market. It has 34 candidates in its pipeline. But it doesn’t have profit sharing with partners.

The mRNA-1273 vaccine is currently the COVID-19 vaccine closest to being developed in the U.S., though its results won’t be known for months. This vaccine’s success is due to a messenger RNA delivery system that transfers information from DNA to cell machinery. It might also prove useful in cancer immunotherapy.

Other biotechs are developing COVID-19 vaccines. BioNTech SE and Vir Biotechnology are two companies that have partnered with big pharmaceutical companies to develop vaccines. However, many small biotechs might not be able to capitalize on these innovative technologies.

AXS-05 as a depression treatment could be a blockbuster drug

Earlier this month, Axsome Therapeutics (NASDAQ:AXSM) announced that the FDA accepted the company’s application for its novel antidepressant therapy, AXS-05. AXS-05 is an oral investigational NMDA receptor antagonist. It is currently under FDA review, and is expected to receive FDA approval this quarter.

Axsome is a clinical-stage biotechnology company, with two lead candidates in major depressive disorder and migraine treatment. Axsome recently acquired Sunosi, a clinical-stage drug previously developed by Jazz Pharmaceuticals. AXS-05 is an investigational NMDA receptor antagonist, and has a novel mechanism of action. It is currently undergoing late-stage clinical trials. Axsome also has a new pipeline product, AXS-14, which is an investigational treatment for fibromyalgia.

AXS-05 is an investigational drug that is under priority review by the FDA. It is a combination of dextromethorphan and bupropion. It is an antidepressant that has been shown to have rapid onset of action and sustained antidepressive effects in clinical trials. AXS-05 has the potential to become a blockbuster drug. GlobalData estimates that AXS-05 could reach US$1.3 billion in global sales by 2029.

AXS-05 has been studied in a phase 3 trial, and has demonstrated sustained antidepressive effects. In addition, AXS-05 showed a statistically significant reduction in MADRS, a scoring system for the severity of symptoms. It also demonstrated a significant reduction in the rate of relapse. In the double-blind treatment period, the rate of relapse was just over 0%.

Gilead Sciences

Whether you’re a seasoned investor or a newbie, there are a few things you should know about Gilead Sciences. They’re a biotechnology company that specializes in the research and development of innovative medicines. They have a primary focus on HIV and oncology drugs. They have products such as Veklury and Biktarvy. They also have a number of drugs used to treat influenza, hepatitis B, and hepatitis C.

There are many reasons why Gilead Sciences is a good investment. The stock has been dependable, offers a good dividend yield, and offers investors a chance to participate in the growth of the biotechnology industry. It’s also one of the few biotechnology stocks that offers investors a chance to make money from the development of innovative medicines.

The company had a number of partnerships with other healthcare companies. One of these was with Galapagos to develop a drug called filgotinib. The drug cured HCV in most patients. However, Gilead failed to gain many new patients with its HCV drug.

In Q2, Gilead’s HIV drugs generated more than two-thirds of its revenue. During the same period, Veklury’s sales dwindled. It appears that the new COVID-19 wave may boost Veklury’s sales.

Fortunately, Gilead has other products on its pipeline that can boost its growth. It’s developing a new messenger RNA HIV vaccine. It’s also researching cancer-therapy research. It’s also researching a new therapy for muscle cramps.

Leave a Reply

Your email address will not be published.